Spots Global Cancer Trial Database for systemic mastocytosis
Every month we try and update this database with for systemic mastocytosis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Patient-Reported Outcome Questionnaire for Systemic Mastocytosis | NCT02380222 | Aggressive Syst... SM w Assoc Clon... Mast Cell Leuke... Smoldering Syst... Indolent System... | Interview | 18 Years - | Adelphi Values LLC | |
| Diagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis | NCT02441166 | Systemic Mastoc... | Mastocytosis di... | 18 Years - | University Hospital, Toulouse | |
| Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals | NCT00001760 | Atopic Dermatit... Healthy Mastocytosis | - | National Institutes of Health Clinical Center (CC) | ||
| A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | NCT00109707 | Chronic Myeloge... Acute Lymphobla... Hypereosinophil... Systemic Mastoc... | Nilotinib | 18 Years - | Novartis | |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | NCT04681105 | Recurrent Acute... Recurrent B Acu... Recurrent Blast... Recurrent Chron... Recurrent Hairy... Recurrent Hemat... Recurrent Hodgk... Recurrent T Acu... Refractory Acut... Refractory B Ac... Refractory Blas... Refractory Chro... Refractory Hair... Refractory Hema... Refractory Hodg... Refractory T Ac... Systemic Mastoc... | Acetaminophen Dexamethasone Diphenhydramine Flotetuzumab Ibuprofen Ranitidine | 12 Years - | City of Hope Medical Center | |
| Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes | NCT00171912 | Hypereosinophil... Systemic Mastoc... Chronic Myelomo... Dermatofibrosar... | imatinib mesyla... | 16 Years - 80 Years | Novartis | |
| Study of Mast Cell Precursors | NCT00001756 | Mastocytosis Healthy Volunte... | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | ||
| Treatment of Indolent Systemic Mastocytosis With PA101 | NCT02478957 | Mastocytosis Systemic Mastoc... Indolent System... | PA101 Placebo | 18 Years - 75 Years | Patara Pharma | |
| Imatinib in KIT-negative Systemic Mastocytosis | NCT01297777 | Systemic Mastoc... | Imatinib Mesyla... | 18 Years - | Hospital Virgen de la Salud | |
| Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) | NCT00493129 | Leukemia Systemic Mastoc... | Ontak (Denileuk... | - | M.D. Anderson Cancer Center | |
| Obatoclax for Systemic Mastocytosis | NCT00918931 | Leukemia Systemic Mastoc... | Obatoclax Mesyl... | 18 Years - | M.D. Anderson Cancer Center | |
| Treatment of Indolent Systemic Mastocytosis With PA101 | NCT02478957 | Mastocytosis Systemic Mastoc... Indolent System... | PA101 Placebo | 18 Years - 75 Years | Patara Pharma | |
| Mast Cell Connect: A Registry for Patients With Mastocytosis | NCT02620254 | Mastocytosis | - | Blueprint Medicines Corporation | ||
| Mast Cell Connect: A Registry for Patients With Mastocytosis | NCT02620254 | Mastocytosis | - | Blueprint Medicines Corporation | ||
| Use of Tamoxifen in Systemic Mastocytosis | NCT01334996 | Systemic Mastoc... | 21 Years - | Mayo Clinic | ||
| GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | NCT03214666 | High-risk Myelo... Acute Myelogeno... Systemic Mastoc... Mast Cell Leuke... | GTB-3550 TriKE®... GTB-3550 TriKE®... | 18 Years - | GT Biopharma, Inc. | |
| (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | NCT04996875 | Advanced System... SM With an Asso... Mast Cell Leuke... Aggressive Syst... | bezuclastinib | 18 Years - | Cogent Biosciences, Inc. | |
| Evaluation of Response of Dasatinib to Treat Mastocytosis | NCT00979160 | Systemic Mastoc... | Dasatinib | 18 Years - | Federico II University | |
| Angioedema Biomarker Research Study | NCT06210698 | Angioedema Angioedemas, He... Urticaria Mastocytosis ACE Inhibitor-I... C1 Inhibitor De... Systemic Mastoc... Indolent System... | Venipuncture | 12 Years - 75 Years | Foundation For Rare Disease Research | |
| Patient-Reported Outcome Questionnaire for Systemic Mastocytosis | NCT02380222 | Aggressive Syst... SM w Assoc Clon... Mast Cell Leuke... Smoldering Syst... Indolent System... | Interview | 18 Years - | Adelphi Values LLC | |
| Use of Tamoxifen in Systemic Mastocytosis | NCT01334996 | Systemic Mastoc... | 21 Years - | Mayo Clinic | ||
| Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis | NCT00449748 | Systemic Mastoc... | RAD001 (Everoli... | 18 Years - | M.D. Anderson Cancer Center | |
| Patient-Reported Outcome Questionnaire for Systemic Mastocytosis | NCT02380222 | Aggressive Syst... SM w Assoc Clon... Mast Cell Leuke... Smoldering Syst... Indolent System... | Interview | 18 Years - | Adelphi Values LLC | |
| Imatinib in KIT-negative Systemic Mastocytosis | NCT01297777 | Systemic Mastoc... | Imatinib Mesyla... | 18 Years - | Hospital Virgen de la Salud | |
| Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis | NCT00449748 | Systemic Mastoc... | RAD001 (Everoli... | 18 Years - | M.D. Anderson Cancer Center | |
| (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | NCT05186753 | SSM Mastocytosis, I... Mastocytosis, S... Mastocytosis | Bezuclastinib T... Bezuclastinib T... Placebo Tablets | 18 Years - | Cogent Biosciences, Inc. | |
| Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) | NCT00493129 | Leukemia Systemic Mastoc... | Ontak (Denileuk... | - | M.D. Anderson Cancer Center | |
| Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia | NCT01807598 | Aggressive Syst... Mast Cell Leuke... Systemic Mastoc... | Brentuximab ved... | 18 Years - | Stanford University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
